Evaluation effects of colchicine on reducing depression in patient with heart failure

Evaluation effects of colchicine on reducing depression in patient with heart failure with reduced ejection fraction: randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111206008307N43

Enrollment

Registered

2022-12-07

Start date

2022-12-11

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure. Systolic (congestive) heart failure

Interventions

Intervention 1: Intervention group: Patients will receive 25 mg of empagliflozin daily for three months with standard treatments. Intervention 2: Control group: Patients will receive 10 mg empaglifloz

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Heart failure with reduced ejection fraction Consented patients Aged 18 to 80 years

Exclusion criteria

Exclusion criteria: History of using colchicine Patient with liver and kidney disease Patient with inflammatory and autoimmune disease Pregnant woman Breastfeeding woman Patient with major depression Patient with symptomatic hypotention Contraindications of colchicine

Design outcomes

Primary

Measure	Time frame
Hamilton score chek list. Timepoint: Before intervention and 1, and 3 months after intervention. Method of measurement: Hamilton depression checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTaher Entezari-Maleki

Tabriz University of Medical Sciences

tentezari@gmail.com+98 912 635 0900

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026